C7orf52 Inhibitors
The chemical class termed C7orf52 Inhibitors comprises a diverse set of compounds targeting specific cellular pathways associated with the protein. TPCA-1 inhibits IKK, preventing NF-κB activation, and JSH-23 inhibits NF-κB activation, impacting inflammatory responses. LY2409881, a p70S6 kinase inhibitor, disrupts mTORC1 signaling, potentially affecting downstream events linked to C7orf52. BAY 11-7082 inhibits NF-κB activation, influencing inflammatory responses and cellular processes. SB-203580 inhibits p38 MAPK, potentially impacting cellular events associated with C7orf52. SP600125 inhibits JNK, influencing MAPK signaling, and Rapamycin inhibits mTOR, disrupting the mTOR signaling pathway, both potentially affecting downstream events associated with C7orf52.
U0126 inhibits MEK1/2, potentially disrupting the MAPK/ERK signaling cascade linked to C7orf52. NSC23766 inhibits Rac1, influencing multiple signaling pathways, and SP2509 inhibits BRD4, impacting epigenetic regulation. PI-103, a dual PI3K/mTOR inhibitor, disrupts both PI3K and mTOR signaling pathways, and PD98059 inhibits MEK1, an upstream regulator of ERK1/2. Collectively, these inhibitors form a class with diverse mechanisms, collectively influencing cellular processes associated with C7orf52.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 inhibits IκB kinase (IKK), preventing NF-κB activation. Inhibition of NF-κB signaling can potentially influence cellular processes associated with C7orf52. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 inhibits NF-κB activation, impacting inflammatory responses. Inhibition of NF-κB may indirectly influence cellular processes related to C7orf52. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, a key transcription factor. Inhibition of NF-κB signaling may influence inflammatory responses and cellular processes associated with C7orf52. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 inhibits p38 MAPK, disrupting the p38 MAPK signaling pathway. Inhibition of p38 MAPK may impact cellular events associated with C7orf52. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), influencing MAPK signaling. Inhibition of JNK may potentially affect cellular processes linked to C7orf52. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, disrupting the mTOR signaling pathway. Inhibition of mTOR can potentially impact downstream events associated with C7orf52. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components of the MAPK/ERK pathway. Inhibition of MEK1/2 may disrupt the MAPK/ERK signaling cascade, potentially influencing cellular processes related to C7orf52. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual PI3K/mTOR inhibitor, disrupting both PI3K and mTOR signaling pathways. Inhibition of these pathways may potentially affect downstream events related to C7orf52. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1, an upstream regulator of ERK1/2. Inhibition of MEK1 may disrupt the MAPK/ERK pathway, potentially influencing cellular events associated with C7orf52. | ||||||